Oragenics (OGEN) announced that it has regained full compliance with NYSE American’s continued listing standards and is positioning the company to focus exclusively on advancing its lead clinical program.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGEN:
- Oragenics, Receptor.AI partner to accelerate pipeline development
- Oragenics Appoints Natasha Giordano to Board of Directors